News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
CSL Limited Plans A$900 (US$815) Million Share Buyback After Net Profit Slips
August 18, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Wall Street Journal -- SYDNEY—CSL Ltd. said its full-year net profit fell 8% and the company unveiled a 900 million Australian dollar (US$815 million) share buyback.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Asia
Australia
MORE ON THIS TOPIC
Manufacturing
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
September 22, 2026
·
2 min read
·
Nick Paul Taylor
IPO
2026 IPO blitz continues with 4 new biotech filings
September 22, 2026
·
4 min read
·
Tristan Manalac
Cancer
Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics
September 22, 2026
·
2 min read
·
Tristan Manalac
Layoff Tracker
BMS says goodbye to 265 New Jersey staff as reorg rolls on
September 22, 2026
·
95 min read
·
BioSpace Editorial Staff
